Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
MNMD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
fool.com
5 hours ago
businesswire.com
16 hours ago
businesswire.com
16 hours ago
fool.com
18 hours ago
seekingalpha.com
21 hours ago
Quote Panel
Key Metrics
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.53
vs -0.56
Q4.23
N/A
-0.59
vs -0.27
Q1.24
N/A
-0.60
vs -0.51
Q2.24
N/A
-0.48
vs -0.72
Q3.24
N/A
-0.27
vs -0.53
Q4.24
N/A
-0.41
vs -0.59
Q1.25
N/A
-0.35
vs -0.60
Q2.25
N/A
-0.50
vs -0.48
Q3.25
N/A
-0.50
vs -0.27
Q4.25
N/A
-0.51
vs -0.41
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
4.8M vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
-100%
NA vs 4.8M
Q1.25
NA
NA vs NA
Q2.25
NA
NA vs NA
Return on Equity
QoQ
Q1.23
-19%
-0.19
vs 0.03
Q2.23
-27%
-0.27
vs -0.19
Q3.23
-19%
-0.19
vs -0.27
Q4.23
-31%
-0.31
vs -0.19
Q1.24
-28%
-0.28
vs -0.31
Q2.24
-3%
-0.03
vs -0.28
Q3.24
-5%
-0.05
vs -0.03
Q4.24
-14%
-0.14
vs -0.05
Q1.25
-10%
-0.10
vs -0.14
Q2.25
-23%
-0.23
vs -0.10
Institutionnal Ownership
QoQ
Q4.22
98
98
vs 76
29%
Q1.23
88
88
vs 98
-10%
Q2.23
87
87
vs 88
-1%
Q3.23
96
96
vs 87
10%
Q4.23
107
107
vs 96
11%
Q1.24
147
147
vs 107
37%
Q2.24
164
164
vs 147
12%
Q3.24
169
169
vs 164
3%
Q4.24
183
183
vs 169
8%
Q1.25
197
197
vs 183
8%
Forecast
2026-Revenue
-270%2026-EPS
2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(N/A)
Number of analyst
0
Last analyst upgrade/downgrade
RBC Capital
initialisePrevious: Not converted
2022-11-16
Now: Outperform
Oppenheimer
initialisePrevious: Not converted
2022-08-26
Now: Outperform
Relative Strength
MNMD
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
NASDAQ
Unprofitable
Unprofitable
0.14 ( 1.46%)
Relative Strenght
88
Volume Buzz
-26%
Earning Acce
No
Dist 52w H.
7%